Tests distributed
Global rapid diagnostic test deliveries across diseasesmillion tests
Malaria testing dominates worldwide supplies, with manufacturers delivering 3,900 million tests between 2010 and 2022, while targeted programs for cholera deployed just 1.2 million.
The numbers
| 1 | Malaria (Cumulative deliveries by manufacturers, 2010–2022) | 3,900 | 55% |
| 2 | Malaria (PMI cumulative distributed, 2005–2020) | 484 | 6.8% |
| 3 | Malaria (Delivered by manufacturers, 2021) | 413 | 5.8% |
| 4 | Malaria (Sold by manufacturers, 2019) | 348 | 4.9% |
| 5 | Malaria (National malaria programmes distributed, 2022) | 345 | 4.9% |
| 6 | Malaria (National malaria programmes distributed, 2023) | 345 | 4.9% |
| 7 | Malaria (National malaria programmes distributed, 2019) | 267 | 3.8% |
| 8 | Malaria (National malaria programmes distributed, 2021) | 262 | 3.7% |
| 9 | Malaria (National malaria programmes distributed, 2020) | 262 | 3.7% |
| 10 | HIV (Rapid tests distributed worldwide, 2021) | 176 | 2.5% |
| 11 | COVID-19 (ACT-A / WHO / partners LMIC allocation agreement, 2020) | 120 | 1.7% |
| 12 | Malaria (Global Fund supported programs distributed, 2005–2010) | 61.1 | 0.9% |
| 13 | COVID-19 (WHO diagnostic tests delivered globally, 2020–2021) | 43 | 0.6% |
| 14 | COVID-19 (ACT-A delivered to LMICs, Q1 2022) | 16 | 0.2% |
| 15 | Malaria (UNICEF delivered to 17 countries, 2022) | 15.06 | 0.2% |
| 16 | Dual HIV/Syphilis (Global Fund PPM procured, 2023) | 12 | 0.2% |
| 17 | HIV Self-Tests (Global Fund PPM procured, 2023) | 10 | 0.1% |
| 18 | Dual HIV/Syphilis (Global Fund PPM procured, 2022) | 7 | 0.1% |
| 19 | Dual HIV/Syphilis (Major donors & governments procured, 2020) | 5 | 0.1% |
| 20 | Tuberculosis (Global Fund next-gen NPOC deployment target, by end 2026) | 3 | 0.0% |
| 21 | Cholera (Gavi/UNICEF/WHO global deployment program, 2024) | 1.2 | 0.0% |